Founded in 2002, Qbtech provides in-off ice and telehealth ADHD testing and is transforming ADHD care through a technology-first approach. Qbtech developed the first FDA-cleared objective tests for ADHD evaluation and treatment monitoring. These objective tests streamline the ADHD assessment process and help clinicians, patients and their families to gain a better understanding of core ADHD symptoms.
Qbtech measures symptoms by combining a computer- based task with motion capture cameras, bringing more objectivity to evaluation and treatment. The company provides clinicians with industry-leading technology to clearly measure ADHD symptoms and tools and training for more confident decisions.
Technology
QbTest
FDA-cleared for diagnosis and treatment evaluation for ages 6-60
In-clinic assessment conducted with a qualified healthcare provider
Results delivered in a visual report, comparing the patient’s results to others in their age range and gender without ADHD.
BENEFITS
According to published data from the AQUA Study, clinicians were statistically more confident when they had QbTest results available than when these results were withheld or unavailable during the evaluation process.
The benefits of Qbtech products in practiceare substantial, both for healthcare providers and patients:
Improved access to care
Elevated clinician confidence in diagnosis
50% better identification of treatment effects than self-report rating scales (ASRS)
Standardization of care across multiple disciplines. For patients, we know that seeking an evaluation can be quite intimidating and you may have a lot of questions, you aren’t sure where to turn. We have added in this type of objective testing because we have heard from patients that:
It is easy to do, yes it is boring, but because it doesn’t involve things like language, reading or math, it is not intellectually difficult
patients get a better understanding of what their levels of activity, impulse control and attention looks like during the testing period and also being able to visually compare themselves to someone of their same age and gender at birth
being able to measure how your treatment is working in a short, yet objective manner can lead to improved discussions with your clinician.
In Action
Qbtech products have been adopted across 43 states in the U.S. and at the national level by organizations such as the NHS in England in over 120 sites. They have been documented in more than 35 independent studies in diagnosis and treatment optimization, showing benefits across the patient care pathway. In March 2022, Qbtech received the Best in Mental Health Partnership Award for work with the AHSN National Program in the NHS of England.
